Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 6/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27920110 | 0.84 | XDH (0.43) | FFAR1XDHAR | |
| SCHEMBL31019133 | 0.82 | XDH (0.53) | XDHSLC22A12 | |
| SCHEMBL2344031 | 0.82 | XDH (0.53) | XDHSLC22A12 | |
| SCHEMBL12455378 | 0.82 | MRGPRX4 (0.48) | ALDH1A1GAAXDHSLC22A12AR | |
| SCHEMBL944720 | 0.81 | TRPV4 (0.53) | ALDH1A1GAAFFAR1AR | |
| SCHEMBL3746804 | 0.81 | AR (0.50) | ALDH1A1GAAFFAR1XDHAR | |
| SCHEMBL27750629 | 0.81 | ALDH1A1 (0.42) | ALDH1A1GAAXDHSLC22A12SLC6A9 | |
| SCHEMBL17309854 | 0.81 | SLC6A9 (0.47) | ALDH1A1GAAXDHSLC22A12AR | |
| SCHEMBL6627537 | 0.81 | AR (0.40) | ALDH1A1GAAFFAR1ARNR3C1 | |
| SCHEMBL11398569 | 0.80 | FFAR1 (0.42) | ALDH1A1FFAR1ARKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | claimed |
| CN-101863854-A | Synthesis method of 2-(3-cyan-4-isobutoxy) phenyl-4-methyl-5-thiazole formic acid | UNIV SHENYANG PHARMACEUTICAL | 2010-10-20 | — | — | CN | claimed |
| CN-103333134-B | 2-(3-cyano group-4-alkoxyl group) phenyl-4-substituted thiazole-5-formic acid compound, composition and method of making the same and purposes | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-02-24 | — | — | CN | disclosed |
| CN-102276550-B | The synthetic method of 2-aryl nitrile thiazole derivative and intermediate thereof | JIUZHOU PHARMACEUTICAL CO., LTD., ZHEJIANG (CN) | 2015-08-19 | — | — | CN | disclosed |
| US-20140228417-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS | MAPI PHARMA LTD. (IL) | 2014-08-14 | — | — | US | disclosed |
| EP-2763675-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS | Mapi Pharma Limited (IL) | 2014-08-13 | — | — | EP | disclosed |
| CN-103333134-A | 2-(3-cyano-4-alkoxy) phenyl-4-substituted thiazole-5-formic acid compound, composition as well as preparation methods and applications thereof | UNIV SHENYANG PHARMACEUTICAL | 2013-10-02 | — | — | CN | disclosed |
| WO-2013050996-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS | MAPI PHARMA LTD. (IL) | 2013-04-11 | — | — | WO | disclosed |
| CN-102276550-A | Method for synthesizing 2-aryl nitrile thiazole derivative and intermediate thereof | — | 2011-12-14 | — | — | CN | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141933-A2 | PROCESS FOR PREPARATION OF 2-[3-CYANO-4-(2-METHYLPROPOXY)PHENYL]-4-METHYLTHIAZOLE-5-CARBOXYLIC ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| EP-2266966-A1 | A process for the preparation of febuxostat | Chemo Ibérica, S.A. (ES) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010142653-A1 | A PROCESS FOR THE PREPARATION OF FEBUXOSTAT | CHEMO IBÉRICA, S.A. (ES) | 2010-12-16 | — | — | WO | disclosed |
| CN-101863854-A | Synthesis method of 2-(3-cyan-4-isobutoxy) phenyl-4-methyl-5-thiazole formic acid | UNIV SHENYANG PHARMACEUTICAL | 2010-10-20 | — | — | CN | disclosed |
| CN-101863854-A | Synthesis method of 2-(3-cyan-4-isobutoxy) phenyl-4-methyl-5-thiazole formic acid | UNIV SHENYANG PHARMACEUTICAL | 2010-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228417-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 2-ARYLTHIAZOLE CARBOXYLIC ACIDS | XDH, NLRP3, PNPO | ALDH1A1 241/4885GAA 713/4885FFAR1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.